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The reproducible crystallisation of elusive polymorphs and solvates of molecular compounds at high
pressure has been demonstrated through studies on maleic acid, malonamide, and paracetamol. These
high-pressure methods can be scaled-up to produce ‘bulk’ quantities of metastable forms that can be
recovered to ambient pressure for subsequent seeding experiments. This has been demonstrated for
paracetamol form II and paracetamol monohydrate. The studies also show that the particular solid
form can be tuned by both pressure and concentration.
Introduction
The importance of polymorphism and solvate formation in the
crystallisation of organic compounds is widely recognised within
the industrial and academic communities.1 The solid-state
properties (and hence crystal structure) of a compound can affect
other properties such as the bioavailability of a drug compound,
the colour of a pigment, and the shock-sensitivity of an explosive.
Intellectual property can also become an issue for pharmaceu-
tical companies who develop and market new drug products,
where challenges to patents have been made on the basis of the
discovery of a new polymorph or solvate. Substantial effort is
therefore deployed in order to explore fully the polymorphic
behaviour of emerging drug products. Generally the techniques
used for polymorph screening involve recrystallisations from
a wide range of solvents under a variety of conditions, and high-
throughput robotic screening is increasingly being used.2,3 One of
the aims of such studies is to identify the controlled conditions
required to ensure that a particular polymorph or solvate can be
reproducibly obtained. However, Dunitz and Bernstein have
highlighted several examples where this reproducibility has been
shown to be very difficult to achieve and cite examples where
apparent loss of control of the crystallisation procedure results in
an inability to obtain the desired form even though this form had
previously been routinely obtained over long periods of time.4
The authors discussed the concept of ‘‘disappearing’’ or elusive
polymorphs and described situations where a polymorph may
only be observed once before a new, more thermodynamically
stable polymorph is crystallised. The crystallisation of the second
form results in the ‘disappearance’ of the previous polymorph
and repeated attempts to grow the original polymorph are
unsuccessful despite using the same crystallisation conditions.
Several of the examples of ‘disappearing’ polymorphs given in
their review illustrated the importance of seed crystallites in the
formation of the stable polymorph—once seed crystallites of the
more stable form were present in the laboratory it proved
impossible to obtain the other polymorphs.4 The example of
benzocaine picrate was one where the original polymorph could
be found again, but at a cost of cleaning the entire laboratory and
waiting 8–12 days. Another example was that of 1,2,3,5-tetra-O-
acetyl-b-D-ribofuranose, which warned that the loss of a partic-
ular polymorph can be a global problem and not just restricted to
a one specific laboratory.4 There are numerous other examples
of compounds where, although not impossible, it is often difficult
to obtain one polymorph at the expense of another.5 It is for
this reason that various crystallisation strategies have been
developed. These include: crystallisation in the presence of
additives;6–10 co-crystallisation;11–13 flash cryo-crystallisation;14
and hydrothermal methods.15
Another method that has proved to be successful for the
exploration of polymorphism in molecular compounds is the use
of high pressure.16 Examples include simple alcohols17,18 and
carboxylic acids;19,20 mineral acids and their hydrates;21,22 poly-
cyclic aromatic hydrocarbons;23 chloroalkanes and chlor-
osilanes;24,25 pharmaceutical compounds such as paracetamol
and piracetam;26,27 amino acids;28–30 explosives;31 and inorganic
coordination compounds.32 Nevertheless, the study of molecular
systems using high pressure remains as an emerging field, and at
this stage its true potential as a tool for the control of poly-
morphism and solvate formation has yet to be fully realised.
In this paper we use three examples to demonstrate how high-
pressure methods can be used to obtain apparently elusive
crystalline forms. We also show how these methods can be scaled
up to recover to ambient pressure ‘‘bulk’’ quantities of these
phases. The three examples (see Fig. 1 for molecular structures)
are maleic acid, malonamide and paracetamol (acetaminophen).
Our attention was drawn to these compounds not only by the
difficulty in obtaining the elusive form, but also by the densities
of the various forms. For all three compounds the crystal density
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(calculated from the X-ray diffraction parameters at similar
temperatures) of the elusive polymorph was significantly greater
than the densities of the other more prevalent polymorph(s).
Since high-pressure conditions frequently favour the formation
of higher density forms, our intention was to discover whether
the application of high-pressure techniques could be used to
obtain these elusive polymorphs in a reproducible manner.
Results and discussion
Example 1 - maleic acid
Maleic acid is used widely in the pharmaceutical industry as
a salt-forming agent and so is a good example of a compound
that has been recrystallised from solution literally thousands of
times. The results of all structural studies up to 2006 strongly
suggested that the compound was monomorphic.33,34,35 However,
Day et al. recently obtained and characterised a new polymorph
(form II) by dissolution in chloroform of the 1 : 2 adduct formed
between maleic acid and caffeine, followed by slow evapora-
tion.36 With admirable honesty, the authors reported that
unfortunately they were unable to obtain this new form again
and remarked that ‘‘.this is possibly another case of disappearing
polymorphism.’’.
Both forms of maleic acid contain identical, hydrogen-bonded,
polar sheets (Fig. 2) in which the carbonyl groups point in similar
directions. The difference between the forms lies in the rela-
tionship between adjacent sheets. In form I, the sheets that are
formed above and below are aligned in the opposite direction
from the central sheet (see Fig. 2). This results in the adoption of
a centrosymmetric space group (P21/c). In form II (see Fig. 3),
each sheet is pointing in the same direction resulting in the
adoption of a non-centrosymmetric space group (Pc). The
densities of forms I and II at 180 K are 1.643 and 1.661 g cm3,
respectively.36
X-Ray powder diffraction patterns were recorded at 293 K
over a series of pressures up to 4.2 GPa for a polycrystalline
sample of form I contained in a Merrill-Bassett diamond-anvil
cell (DAC) with Fluorinert-FC75 acting as a pressure-trans-
mitting medium. These measurements showed that there was no
transition to form II. Instead, a smooth (12%) decrease in unit-
cell volume was observed over this pressure range, with the
largest decrease being along the direction of the a-axis. This is
parallel to the hydrogen-bonded chains within the layers (see
Fig. 4). This result supports the suggestion by Day et al. that
stress-induced interconversion between forms I and II would be
unlikely on account of their different stacking patterns which
would result in a significant barrier to transformation.36
An alternative approach was therefore adopted which
involved the dissolution of maleic acid to give a saturated
Fig. 1 Molecular structures of maleic acid, malonamide, and para-
cetamol.
Fig. 2 View of crystal structure of maleic acid form I showing adjacent
layers aligned in opposite directions.
Fig. 3 View of crystal structure of maleic acid form II showing adjacent
layers aligned in the same direction.
Fig. 4 View of hydrogen-bonded layer of maleic acid form I showing the
direction of greatest compression along the a-axis.
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aqueous solution. On loading this solution into a DAC and
raising the pressure rapidly to 1.6 GPa, a polycrystalline
powder was formed. X-Ray powder diffraction measurements
showed the presence of high-pressure ice-VI and another poly-
crystalline phase. By reducing the pressure to 0.6 GPa the
Bragg peaks due to ice disappeared and the remaining phase was
indexed as form II (see Fig. 5).
Subsequent experiments using a range of concentrations of
aqueous maleic acid solutions showed that the presence of ice-VI
was in fact not required in order to precipitate form II; crystal-
lisation at pressures above 0.5 GPa invariably gave form II. It
also proved possible to grow a single crystal from this precipitate
at 0.5 GPa by cycling the temperature of the DAC. Care was
required during this process in order to avoid temperature-
induced isomerism to the thermodynamically more stable (and
significantly less soluble) fumaric acid, especially as there was
some evidence that this isomerisation occurred more readily
under elevated pressures. This is consistent with an early study
involving the thiocyanate-catalysed isomerism of maleic acid at
pressures up to 0.5 GPa which showed that the rate of this
reaction increased with increasing pressure.37 Single-crystal X-
ray diffraction measurements identified the crystal as maleic acid
form II. On decompression to ambient pressure the single crystal
was observed to dissolve, in line with the increased solubility of
maleic acid at lower pressure. Similar observations were made on
decompression of polycrystalline samples and it was only
possible to recover solid to ambient pressure when the DAC was
loaded with super-saturated solutions. On these occasions, X-ray
powder diffraction showed that at high pressure (>0.5 GPa) only
form II was produced. Form II persisted on decompression to
lower pressures ( 0.2 GPa), but when the pressure was
completely released such that the DAC was no longer sealed,
additional diffraction peaks attributable to form I were
observed. We suspect that this form was produced by partial
evaporation of the solution from the edge of the gasket. Judging
from the diffraction patterns recorded after several hours, there
appeared to be no change in the relative proportions of the two
forms or in the texture of the powder patterns. This was rather
surprising since although direct interconversion is hindered, the
presence of water should allow a solvent-mediated transition if
form I is appreciably more stable than form II. Hence one
possible interpretation is that under these conditions both forms
have almost equal thermodynamic stabilities. Support for this
comes from the calculated lattice energy difference between the
two forms of 0.15 kJ mol1 obtained by Day et al.36 On the other
hand, it could be that in the absence of stirring the process of
interconversion is kinetically slow, and so complete conversion
to the more stable form does not occur over this relatively short
time period.
Not surprisingly, given the similarities in structural motif, the
Raman spectra of both polymorphs in the range 200–3000 cm1
are almost indistinguishable, although there is a variation in the
relative intensities of the two bands near 1700 cm1. However,
one distinct difference was observed in the region near 300 cm1
(Fig. 6)—form I displays three well defined bands whilst at the
same pressure two of these bands overlap in the spectrum of
form II.
Repeated attempts to produce form II at ambient pressure
from aqueous solution, including flash cooling and crystal-
lisation in the presence of ice, were unsuccessful. Crystallisation
from the high-temperature melt also failed to produce form II.
This is in contrast to the ease with which form II can be repro-
ducibly (> 15 times) crystallised at pressures above 0.5 GPa from
aqueous solution. These observations strongly suggest that form
II is the thermodynamically more stable form at elevated pres-
sures and demonstrate how high pressure can be used to influ-
ence the outcomes of crystallisation. It remains to be seen
whether a full polymorph screen at ambient pressure using
a range of conditions including selected additives would be able
to identify the conditions required for the reproducible crystal-
lisation of form II.
Example 2 - malonamide
Three crystalline forms of malonamide have been identified and
structurally characterised. The monoclinic form I can be
Fig. 5 Powder X-ray diffraction pattern recorded for maleic acid form II
at 0.6 GPa using radiation of wavelength 0.44397 A˚. Note that the
preferred orientation of the sample, combined with the small size of the
incident X-ray beam, has a significant impact on the relative intensities of
the Bragg peaks.
Fig. 6 Raman spectra of form I (upper) and form II (lower) of maleic
acid.
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obtained by recrystallisation from warm water and was first
structurally characterised in 1970;38 it is this form that is
commercially available (Sigma-Aldrich). A tetragonal form II,
obtained from the alkaline hydrolysis of 4,6-dihydroxypyr-
imidine, was recently discovered and structurally characterised by
Nichol and Clegg.39 However, after the original batch of crystals
had been misplaced, it proved impossible, despite numerous
attempts, to reproduce this form. Instead, a third orthorhombic
form III was obtained and the authors speculated that this might
be an example of the phenomenon of ‘‘disappearing poly-
morphs.’’40 The densities of forms I, II, and III at 150 K calculated
from X-ray diffraction measurements are 1.426, 1.546 and 1.427 g
cm3, respectively. Hence high-pressure methods might be
expected to favour the elusive tetragonal form II.
X-Ray powder diffraction patterns were recorded at 293 K
over a series of pressures up to 5.0 GPa for a polycrystalline
sample of the monoclinic form of malonamide contained in
a Merrill-Bassett diamond-anvil cell with 4 : 1 methanol/ethanol
acting as a pressure-transmitting medium. Fig. 7 shows the
sequence of diffraction patterns in the order in which they were
recorded. All of the patterns up to 0.9 GPa could be indexed to
the monoclinic form with a smooth decrease in unit-cell volume.
At 1.3 GPa the pattern became more complex with the growth of
new peaks and a reduction in intensity of some of the original
peaks, suggesting a mixed phase powder pattern. At the next
pressure point (1.8 GPa), the pattern simplified considerably and
could be indexed to the elusive tetragonal form with lattice
parameters a ¼ 5.2183(3) and c ¼ 14.9944(13) A˚. No further
phase transitions were observed up to 5.4 GPa. Progressive
decompression showed that the tetragonal form II persisted to
ambient pressure. The presence of both phases at 1.3 GPa allows
a direct comparison of the molar volumes of the monoclinic and
tetragonal forms at this pressure, and shows that the tetragonal
form II is 6% more dense at this pressure.
It also proved possible to grow a single crystal of malonamide
contained in a diamond-anvil cell by recrystallisation from an
aqueous solution at a pressure of 0.4 GPa. Fig. 8 shows the
optical image of this crystal and single-crystal X-ray diffraction
confirmed that this was also the tetragonal form. The signifi-
cantly lower pressure required for the phase transition in the
solution recrystallisation experiments reflects how the barriers to
solid–solid phase transitions may be substantially reduced by
high-pressure recrystallisation from solution. These observations
strongly suggest that form II is the thermodynamically more
stable form at elevated pressures.
A previous DSC study had demonstrated that a metastable
form of malonamide with a lower melting point and lower
enthalpy of fusion could be obtained by quench cooling the melt
from 443 K to 300 K.41 We used X-ray powder diffraction to
identify this form and showed that it was in fact the tetragonal
form II that formed under these conditions. These results
therefore suggest that although form II is not as elusive as
originally reported, high pressure is a useful tool for changing the
relative thermodynamic stabilities of polymorphs and hence
providing access to metastable forms. This will be demonstrated
more fully in the next example.
Example 3 - paracetamol
Paracetamol (acetaminophen) is a widely used analgesic drug for
which two polymorphic forms have been identified and struc-
turally characterised. A third form has also been observed,42,43
but is so unstable that its crystal structure remains unknown,
although a possible structure has been suggested on the basis of
powder diffraction measurements and theoretical predictions.44
Under ambient conditions the thermodynamically most stable
polymorph is the monoclinic form I, first described by Haisa
et al.45 and followed more recently by more precise structural
determinations at low temperature.46,47 A metastable ortho-
rhombic form II was also first described by Haisa et al.,48 but
subsequent attempts by other workers to obtain single crystals of
this form using Haisa’s method were unsuccessful,42,46,49
although polycrystalline material in this phase can be grown
from the melt.49 Interest in the selective production of form II
stems from its property of undergoing plastic deformation upon
compaction, thereby presenting some potential processing
advantages over form I.50 Nichols et al. showed that single
Fig. 7 Sequence of X-ray powder diffraction patterns recorded for form
I of malonamide with increasing pressure showing the transition to form
II at 1.3 GPa and subsequent recovery of form II to ambient pressure
(wavelength ¼ 0.44397 A˚).
Fig. 8 Optical image of single crystal of tetragonal form II malonamide
grown at 0.4 GPa.
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crystals of form II can be grown by seeding a super-saturated
solution of paracetamol in methylated spirit with a micro-crystal
of form II derived from melt-crystallised paracetamol, but
highlighted the fact that solvent-mediated interconversion to
form I was very facile.47 The densities of forms I and II calculated
from X-ray diffraction measurements are 1.297 and 1.336 g cm3
at 298 K, respectively.47 Form II has also been crystallised
preferentially from aqueous solutions in the presence of selected
polymers,51,7 and also via a process that involves pre-treatment of
a glass vessel with an alkaline solution followed by recrystalli-
sation over a period of weeks.52 Both of these methods highlight
the importance of surface nucleation and/or the presence of
additives in directing the crystallisation process. Very recently it
has been shown that small quantities of form II can be selectively
crystallised by evaporation from the edge of an aqueous solution
I a process termed ‘‘contact line crystallisation’’.6,53 It is clear
from all of these studies that whilst the reproducible preparation
of samples of form II is possible, it is not at all straightforward.
Within the field of high pressure, Boldyreva et al. have
demonstrated that the application of pressures in excess of 4 GPa
to solid form I resulted in conversion to form II, but conversion
was incomplete.54 Our own studies involving recrystallisation of
paracetamol from various solutions under high pressure gave
a 1 : 1 methanol solvate at 0.6 GPa26 and a dihydrate at 1.1
GPa.55 Crystallisation from ethanol at 1.1 GPa gave the ortho-
rhombic form II,55 and this prompted us to explore (a) the extent
to which high-pressure methods could reproducibly be used to
produce form II, and (b) whether this metastable form could be
prepared in larger quantities at high pressure with subsequent
recovery to ambient pressure.
Initial experiments involved repeated high-pressure recrystal-
lisations in diamond-anvil cells of solutions of paracetamol in
acetone (at 0.2 GPa), 1,4-dioxane (at 0.3 GPa), and water (at 0.25
GPa) to give single crystals that were all subsequently identified
by single-crystal X-ray diffraction to be form II. Experiments
were then performed using a larger volume pressure vessel
(UniPress U101) capable of pressurising samples of volume 4
cm3 up to 1.2 GPa. Such a vessel is used routinely in the pressure-
induced enhancement of Diels–Alder and Michael-addition
reactions.56 Thus a series of experiments were performed, which
involved pressurisation of aqueous solutions (3 cm3) of para-
cetamol spanning a range of concentrations (10–150 g dm3)
contained in smooth Pyrex ampoules sealed with a thin Teflon
membrane. The warm ampoules were loaded into the UniPress
apparatus, pressurised to between 0.5 and 1.0 GPa, and were
then allowed to stand at pressure for a period of 10–20 min. Over
this time period the temperature of the ampoules equilibrated
with the temperature of the press, i.e. 293 K. On depressur-
isation to ambient pressure, the ampoules containing the more
concentrated solutions (>20 g dm3) were observed to contain
a polycrystalline, white precipitate, with the quantity of the
precipitate being dependent on the concentration of the solution
(see Fig. 9).
The morphology of the crystallites varied depending on the
concentration—at concentrations >140 g dm3 the crystallites
displayed a prismatic or plate-like habit that is characteristic of
the monoclinic form of anhydrous paracetamol and this was
confirmed by X-ray powder diffraction. At concentrations <20 g
dm3, no precipitate was observed. By contrast, at intermediate
concentrations, crystallites formed as very fine needles that
transformed to prisms and plates over a period of several hours
at 298 K. These prisms and plates were also identified by X-ray
powder diffraction as being the monoclinic form of anhydrous
paracetamol. Attempts to isolate the first-formed crystalline
material by filtration at ambient temperature for subsequent
analysis by X-ray powder diffraction invariably led to poor-
quality powder patterns that were dominated by the monoclinic
anhydrous form I, although there was some tentative evidence
for the presence of an additional phase. It was clear that the
processes of filtration and subsequent manipulation were causing
rapid transformation of the recovered material. For this reason,
it was decided to perform an experiment that would minimise the
degree of sample manipulation and hence reflect more accurately
the initial composition of the sample. Since it had also been
observed that the rate of transformation of the needles to
monoclinic form I could be substantially slowed by cooling the
suspension to 275–280 K, an additional requirement of the
experiment was the ability to cool the sample. Although powder
neutron diffraction would perhaps not be an obvious choice to
study this system, the larger sample volumes required for neutron
studies combined with the low absorption of thermal neutrons by
many materials often allows a much more flexible sample envi-
ronment for neutron scattering experiments compared to X-ray
experiments. For this reason we opted to use the POLARIS
diffractometer at the UK spallation neutron source, ISIS, located
at the STFC Rutherford Appleton Laboratory, UK. Owing to
the very high incoherent scattering associated with H-containing
materials it was necessary to use solutions of perdeuterated
paracetamol-d9 in D2O for these experiments. Inevitably this
raises the question as to whether deuteration significantly affects
the relative stabilities of the two forms, but experiments at
ambient pressure showed no indication of this – recrystallisation
from water and other solvents (methanol, ethanol, acetone)
under a range of cooling conditions and concentrations invari-
ably produced form I. Highly supersaturated solutions of para-
cetamol-d9 in D2O (100 and 133 g dm
3) were loaded into
Suprasil (quartz) ampoules (external diameter 10 mm and wall
thickness 0.25 mm) sealed with a thin Teflon membrane. Each
ampoule contained 4 cm3 of solution and was pressurised to
between 0.5 and 1.0 GPa using the UniPress U101. After main-
taining this pressure for a period of 10–20 min, the sample was
Fig. 9 (a) Aqueous solution of paracetamol prior to loading in pressure
vessel, (b) precipitate of metastable phase recovered after pressurisation.
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depressurised and transferred immediately into a standard
vanadium can cooled to 280 K. The vanadium can containing the
sample was then transferred directly into the POLARIS
diffractometer, which was maintained at a temperature of 280 K
throughout the experiment. For each of the samples no changes
in the powder diffraction patterns were observed over the period
of data collection (2–6 h). Fig. 10 shows the powder pattern
obtained when the more concentrated sample had been pres-
surised to 1.0 GPa. The broad background is caused by scat-
tering from liquid D2O, but Bragg peaks from the precipitated
solid are clearly visible. It proved possible to index and refine
very satisfactorily the pattern to the anhydrous form II of par-
acetamol. No other solid forms were detected in the pattern. A
similar result was obtained when the less concentrated solution
was pressurised to 0.5 GPa. At the end of the experiment the
ampoule was removed and after standing at ambient temperature
for a period of days, large block-shaped crystals were obtained.
These were subsequently identified by single-crystal X-ray
diffraction as form II.
By contrast, when the less concentrated sample was pressur-
ised to 1.0 GPa, a very different diffraction pattern was observed,
which corresponded exclusively to paracetamol monohydrate.
This hydrate has been prepared previously by flash cooling an
aqueous solution of paracetamol containing sodium fumarate,
and although stable at low temperatures the monohydrate
readily dehydrates under ambient conditions to give the anhy-
drous form I.57 A possible explanation for the formation of the
monohydrate at high pressure can be suggested by an examina-
tion of the phase diagram of water. This shows that compression
of water at 298 K to 1.0 GPa results in the formation of ice-VI.
Thus it may be that the presence of ice is responsible for the
nucleation of paracetamol monohydrate at elevated pressures.
Analogous behaviour has been observed for piracetam dihy-
drate, which nucleated in the presence of ice-VI when aqueous
solutions were compressed to 1.3 GPa.27 Formation of ice under
these conditions might be expected to encourage crystallisation
by two mechanisms: (i) removal of water as solid ice will cause
the local concentration of the solution to increase, and (ii) the
formation of ice crystallites provides many more potential
nucleation sites.
It also proved possible to seed at ambient pressure a cold,
saturated, aqueous solution of paracetamol with a few
crystallites of the monohydrate or form II recovered from the
high-pressure experiments. This produced several grams of
crystalline material which displayed either the characteristic
needle-like morphology of the monohydrate or the block-like
morphology of form II, respectively. This illustrates how the
methodology of high-pressure crystallisation on a relatively
small scale can be used to generate metastable forms for use in
seeding experiments at ambient pressure, thus removing the need
for expensive, very large-volume pressure vessels.
These studies show that pressure-induced precipitation from
aqueous solution can be used to prepare and recover to ambient
pressure significant quantities (up to 0.3 g) of metastable forms
of paracetamol, and that control over which form is produced
can be achieved by variation of both concentration and pressure.
These results demonstrate for the first time the preparation of
form II paracetamol from aqueous solution without the
requirement for any additives or surface treatment of the glass.
They are also in agreement with the observation that the
orthorhombic form II is the thermodynamically stable form at
elevated pressures. Support for this comes from the results of
recent high-pressure DSC measurements, which identified the I-
II-liquid triple point at P ¼ 0.259 GPa and T ¼ 489.6 K.58 These
experimental results are also in good agreement with inferences
drawn from topological P–T and V–T phase diagrams, which
estimated the pressure for the I-II equilibrium at 298 K to be
0.299 GPa.59
Conclusions
The results of this study have shown that the application of high
pressure to molecular compounds can be used to obtain in
a reproducible way polymorphs and solvates that are often found
to be elusive using ambient-pressure techniques and which may
be metastable under ambient conditions. This appears to be
particularly true for metastable polymorphs that have higher
densities. In such cases pressure would be expected to favour
denser forms by changing the relative thermodynamic stabilities
of the various forms. Based on the results of high-pressure DSC
measurements this is clearly the situation for paracetamol,58 and
it seems likely that it is also the situation for maleic acid and
malonamide. Thus the use of pressure has the potential to
enhance our control over crystallisation processes and hence
reduce the occurrence of ‘‘disappearing’’ or elusive polymorphs
and solvates.
The examples selected here are relatively simple molecules,
which do not have the complexity of many modern pharma-
ceutical compounds. However, we see no reason why our
methodologies should not be applicable to more complex
compounds; indeed our experience to date suggests that the
substantial conformational flexibility of many of these more
complex molecules may result in significantly richer pressure-
induced polymorphic behaviour.
Part of the success of the solution crystallisation method used
to obtain these metastable forms must also reflect the confined
nature of the diamond-anvil cell or larger volume pressure vessel.
Both provide an environment in which it is possible not only to
exclude atmospheric seed crystallites of more stable forms, but
also ensure that any remaining seed crystallites in solution can be
completely dissolved. Such a strategy is crucial in view of the well
Fig. 10 Neutron powder diffraction pattern recorded for the recovered
orthorhombic form II of paracetamol-d9 on the POLARIS instrument.
Tick marks indicate predicted Bragg peaks. The large hump is caused by
scattering from liquid D2O.
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documented difficulties experienced in crystallisation processes
where the presence of even trace amounts of a more stable form
in the atmosphere or on laboratory glassware may prevent the
crystallisation of the metastable form.4
Finally, we have shown that appreciable quantities of meta-
stable forms can be generated by crystallisation at elevated
pressure with subsequent recovery to ambient pressure. These
recovered forms can then be characterised at ambient pressure or
can be used in seeding experiments at ambient pressure, thus
removing the need for expensive, very large-volume pressure
vessels. This has the potential to make high-pressure crystal-
lisation a very useful tool in materials discovery.
Experimental
High-pressure X-ray experiments were performed using a Merrill-
Bassett diamond anvil cell60 equipped with 600 mm culets and
a tungsten gasket with a 300 mm hole. A 4 : 1 mixture of meth-
anol/ethanol or Fluorinert-FC75 was used as a hydrostatic
pressure medium with a ruby chip acting as the pressure calibrant.
Single-crystal and powder diffraction data were collected at the
STFC Daresbury Laboratory, UK on Stations 16.2SMX and
9.5HPT,61 respectively. Single-crystal data were processed
according to the procedure described by Dawson et al.62 X-Ray
powder diffraction images were processed using FIT2D,63 and
data were manipulated using PowderCell (version 2.3).64 Neutron
powder diffraction data were collected at 280 K using the
POLARIS diffractometer65 at the UK spallation neutron source,
ISIS, located at the STFC Rutherford Appleton Laboratory.
Neutron diffraction data were manipulated using GSAS.66 Par-
acetamol-d9 was prepared by the reaction between acetic anhy-
dride-d6 (QMX Laboratories) and 4-aminophenol-d7 (QMX
Laboratories) in D2O according to a procedure described in ref.
67. Larger volume experiments were performed using a UniPress
U101, with heptane as a pressure-transmitting medium.
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